Management of non-small cell lung cancer;Prise en charge du cancer bronchique non à petites cellules

Revue Medicale de Liege

Volumn 70, Issue 9, 2015, Pages 432-441

  Sibille, A ^a   Paulus, A ^a   Martin, M ^a   Bourhaba, M ^a   Barthelemy N ^a   Radermecker, M ^a   Corhay, J L ^a   Louis, R ^a   Duysinx, B ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Chemotherapy; Non small cell lung cancer; Pulmonary oncology; Radiotherapy

Indexed keywords

CANCER THERAPY; HUMAN; NON SMALL CELL LUNG CANCER; REVIEW; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; INTERDISCIPLINARY COMMUNICATION; LUNG NEOPLASMS; MALE; PATHOLOGY; PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS;

EID: 84941555087     PISSN: 0370629X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143, e1S-29S.
2. Belgian Cancer Registry. http://www.kankerregister. org/cijfers.- Consultation du 28 septembre 2014
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61, 69-90.
4. Weynand B, Dôme F, Geers C, et al. - Belgian consensus guidelines for the subtyping of NSCLC. Belg J Med Oncol, 2010, 4, 155-157.
5. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 2011, 6, 244-285.
6. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J, 2009, 34, 17-41.
7. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143, e211S-250S.
8. De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg, 2014, 45, 787-798.
9. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2007, 2, 706-714.
10. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013, 24, vi89-98.
11. Scagliotti GV. The ALPI Trial: The Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer. Clin Cancer Res, 2005, 11, 5011s-5016s.
12. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg, 2004, 26, 173-182.
13. Group IALT. Cisplatine-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med, 2004, 350, 351-360.
14. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol, 2004, 22, 3852-3859.
15. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 2005, 352, 2589-2597.
16. Strauss GM, Herndon JE, 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central ancer Treatment Group Study Groups. J Clin Oncol, 2008, 26, 5043-5051.
17. Depierre A, Milleron B, Moro-Sibilot D, et al. - Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol, 2002, 20, 247-253.
18. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/ EORTC 08012 multicentre randomised trial and update of systematic review. Lancet, 2007, 369, 1929-1937.
19. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst, 2007, 99, 442-450.
20. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol, 2010, 28, 3138-3145.
21. Song WA, Zhou NK, Wang W, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer : An updated meta-analysis of 13 randomized control trials. J Thorac Oncol, 2010, 5, 510-516.
22. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation : A pooled analysis by the LACE Collaborative Group. J Clin Oncol, 2008, 26, 3552-3559.
23. Group PM-aT. Postoperative radiotherapy in non-small-cell lung cancer : Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet, 1998, 352, 257-263.
24. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy : Results of a meta-analysis of the literature. Lung Cancer, 2005, 49, 13-23.
25. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol, 2006, 1, 611-621.
26. Lim E, Harris G, Patel A, et al. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: Systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol, 2009, 4, 1380-1388.
27. Standards d'Oncologie Respiratoire. http://www. fnclcc.fr/sor.htm. Consultation du 26 septembre 2014
28. Le Pechoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer : A reassessment based on new data. Oncologist, 2011, 16, 672-681.
29. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer : A multicenter phase II trial. J Clin Oncol, 2003, 21, 1752-1759.
30. Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg, 2012, 93, 1807-1812.
31. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer : A phase III randomised controlled trial. Lancet, 2009, 374, 379-386.
32. Rolland E. Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non small cell lung cancer (NSCLC): Two meta-analysis using individual patient data (IPD) from randomized clinical trials. J Thorac Oncol, 2007, 2, S309-10.
33. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol, 1999, 17, 2692-2699.
34. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst, 2011, 103, 1452-1460.
35. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo- Cancerologie NPC 95-01 Study. J Clin Oncol, 2005, 23, 5910-5917.
36. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 2010, 28, 2181-2190.
37. Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer : OLCSG 0007. J Clin Oncol, 2010, 28, 3299-3306.
38. Senan S, Cardenal F, Vansteenkiste J, et al. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol, 2011, 22, 553-558.
39. Surmont V, Smit EF, de Jonge M, et al. Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer : Results from 2 phase I studies. Lung Cancer, 2010, 69, 302-306.
40. Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer : West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol, 2010, 28, 3739-3745.
41. Vokes EE, Herndon JE, 2nd, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer : Cancer and leukemia group B study 9431. J Clin Oncol, 2002, 20, 4191-4198.
42. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer report of a Canadian multicenter randomized trial. J Clin Oncol, 1988, 6, 633-641.
43. Schiller JH, Harrington D, Belani CP, et al. - Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346, 92-98.
44. Group N-sclcC. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ, 1995, 311, 899-909.
45. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362, 2380-2388.
46. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361, 947-957.
47. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13, 239-246.
48. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31, 3327-3334.
49. Wu YL, Fukuoka M, Mok TS, et al. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study. Lung Cancer, 2013, 81, 280-287.
50. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3 : A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31, 3342-3350.
51. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802) : A multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12, 735-742.
52. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol, 2015, 16, 141-151.
53. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC) : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012, 23, vii56-64.
54. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer : An individual patient data meta-analysis. J Natl Cancer Inst, 2007, 99, 847-857.
55. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26, 3543-3551.
56. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer : A meta-analysis of the published literature. J Clin Oncol, 2005, 23, 2926-2936.
57. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer : AVAil. J Clin Oncol, 2009, 27, 1227-1234.
58. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355, 2542-2550.
59. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer : A randomised, double-blind, phase 3 study. Lancet, 2009, 374, 1432-1440.
60. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT) : A double-blind, phase 3, randomised controlled trial. Lancet Oncol, 2012, 13, 247-255.
61. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 2010, 11, 521-529.
62. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18, 2095-2103.
63. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22, 1589-1597.
64. Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol, 2009, 27, 1836-1843.
65. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353, 123-132.
66. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN) : A randomised multicentre, open-label, phase 3 study. Lancet Oncol, 2012, 13, 300-308.